These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

843 related articles for article (PubMed ID: 27965117)

  • 1. High-dose-rate brachytherapy monotherapy without androgen deprivation therapy for intermediate-risk prostate cancer.
    Patel S; Demanes DJ; Ragab O; Zhang M; Veruttipong D; Nguyen K; Park SJ; Marks L; Pantuck A; Steinberg M; Kamrava M
    Brachytherapy; 2017; 16(2):299-305. PubMed ID: 27965117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-Dose-Rate Monotherapy for Localized Prostate Cancer: 10-Year Results.
    Hauswald H; Kamrava MR; Fallon JM; Wang PC; Park SJ; Van T; Borja L; Steinberg ML; Demanes DJ
    Int J Radiat Oncol Biol Phys; 2016 Mar; 94(4):667-74. PubMed ID: 26443877
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes Associated With 3 Treatment Schedules of High-Dose-Rate Brachytherapy Monotherapy for Favorable-Risk Prostate Cancer.
    Jawad MS; Dilworth JT; Gustafson GS; Ye H; Wallace M; Martinez A; Chen PY; Krauss DJ
    Int J Radiat Oncol Biol Phys; 2016 Mar; 94(4):657-66. PubMed ID: 26797541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A combined single high-dose rate brachytherapy boost with hypofractionated external beam radiotherapy results in a high rate of biochemical disease free survival in localised intermediate and high risk prostate cancer patients.
    Joseph N; Taylor C; O'Hara C; Choudhury A; Elliott T; Logue J; Wylie J
    Radiother Oncol; 2016 Nov; 121(2):299-303. PubMed ID: 28029404
    [TBL] [Abstract][Full Text] [Related]  

  • 6. External Beam Radiation Therapy (EBRT) and High-Dose-Rate (HDR) Brachytherapy for Intermediate and High-Risk Prostate Cancer: The Impact of EBRT Volume.
    Tharmalingam H; Tsang Y; Choudhury A; Alonzi R; Wylie J; Ahmed I; Henry A; Heath C; Hoskin PJ
    Int J Radiat Oncol Biol Phys; 2020 Mar; 106(3):525-533. PubMed ID: 31610249
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate Specific Antigen (PSA) as Predicting Marker for Clinical Outcome and Evaluation of Early Toxicity Rate after High-Dose Rate Brachytherapy (HDR-BT) in Combination with Additional External Beam Radiation Therapy (EBRT) for High Risk Prostate Cancer.
    Ecke TH; Huang-Tiel HJ; Golka K; Selinski S; Geis BC; Koswig S; Bathe K; Hallmann S; Gerullis H
    Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27834929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dose escalation with external beam radiation therapy and high-dose-rate brachytherapy combined with long-term androgen deprivation therapy in high and very high risk prostate cancer: Comparison of two consecutive high-dose-rate schemes.
    Olarte A; Cambeiro M; Moreno-Jiménez M; Arbea L; Pérez-Gracia JL; Gil-Bazo I; Pascual I; Aristu J; Martínez-Monge R
    Brachytherapy; 2016; 15(2):127-35. PubMed ID: 26832677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-dose-rate interstitial brachytherapy as monotherapy in one fraction of 20.5 Gy for the treatment of localized prostate cancer: Toxicity and 6-year biochemical results.
    Prada PJ; Ferri M; Cardenal J; Blanco AG; Anchuelo J; Díaz de Cerio I; Vázquez A; Pacheco M; Raba I; Ruiz S
    Brachytherapy; 2018; 17(6):845-851. PubMed ID: 30030111
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined high dose rate brachytherapy and external beam radiotherapy for clinically localised prostate cancer.
    Strouthos I; Chatzikonstantinou G; Zamboglou N; Milickovic N; Papaioannou S; Bon D; Zamboglou C; Rödel C; Baltas D; Tselis N
    Radiother Oncol; 2018 Aug; 128(2):301-307. PubMed ID: 29764692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nationwide multi-institutional retrospective analysis of high-dose-rate brachytherapy combined with external beam radiotherapy for localized prostate cancer: An Asian Prostate HDR-BT Consortium.
    Ishiyama H; Kamitani N; Kawamura H; Kato S; Aoki M; Kariya S; Matsumura T; Kaidu M; Yoshida K; Hashimoto Y; Noda Y; Lim KHC; Kawase T; Takahashi T; Inaba K; Kumano M; Yoshikawa N; Yoshioka Y; Nakamura K; Hiratsuka J; Itami J; Hayakawa K
    Brachytherapy; 2017; 16(3):503-510. PubMed ID: 28222973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes for prostate glands >60 cc treated with low-dose-rate brachytherapy.
    Pham YD; Kittel JA; Reddy CA; Ciezki JP; Klein EA; Stephans KL; Tendulkar RD
    Brachytherapy; 2016; 15(2):163-8. PubMed ID: 26796717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds.
    Grills IS; Martinez AA; Hollander M; Huang R; Goldman K; Chen PY; Gustafson GS
    J Urol; 2004 Mar; 171(3):1098-104. PubMed ID: 14767279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new model using number of needles and androgen deprivation to predict chronic urinary toxicity for high or low dose rate prostate brachytherapy.
    Vargas C; Ghilezan M; Hollander M; Gustafson G; Korman H; Gonzalez J; Martinez A
    J Urol; 2005 Sep; 174(3):882-7. PubMed ID: 16093980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Standard vs Dose-Escalated Radiation Therapy for Patients With Intermediate-Risk Prostate Cancer: The NRG Oncology RTOG 0126 Randomized Clinical Trial.
    Michalski JM; Moughan J; Purdy J; Bosch W; Bruner DW; Bahary JP; Lau H; Duclos M; Parliament M; Morton G; Hamstra D; Seider M; Lock MI; Patel M; Gay H; Vigneault E; Winter K; Sandler H
    JAMA Oncol; 2018 Jun; 4(6):e180039. PubMed ID: 29543933
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long term results of a prospective dose escalation phase-II trial: interstitial pulsed-dose-rate brachytherapy as boost for intermediate- and high-risk prostate cancer.
    Lettmaier S; Lotter M; Kreppner S; Strnad A; Fietkau R; Strnad V
    Radiother Oncol; 2012 Aug; 104(2):181-6. PubMed ID: 22853851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-dose-rate brachytherapy as a monotherapy for favorable-risk prostate cancer: a Phase II trial.
    Barkati M; Williams SG; Foroudi F; Tai KH; Chander S; van Dyk S; See A; Duchesne GM
    Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1889-96. PubMed ID: 21550182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-Dose-Rate Brachytherapy as Monotherapy for Intermediate- and High-Risk Prostate Cancer: Clinical Results for a Median 8-Year Follow-Up.
    Yoshioka Y; Suzuki O; Isohashi F; Seo Y; Okubo H; Yamaguchi H; Oda M; Otani Y; Sumida I; Uemura M; Fujita K; Nagahara A; Ujike T; Kawashima A; Yoshida K; Yamazaki H; Nonomura N; Ogawa K
    Int J Radiat Oncol Biol Phys; 2016 Mar; 94(4):675-82. PubMed ID: 26238951
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of radiation dose escalation with conformal external beam radiotherapy and high-dose-rate brachytherapy combined with long-term androgen suppression in unfavorable prostate cancer: feasibility report.
    Valero J; Cambeiro M; Galán C; Teijeira M; Romero P; Zudaire J; Moreno M; Ciérvide R; Aristu JJ; Martínez-Monge R
    Int J Radiat Oncol Biol Phys; 2010 Feb; 76(2):386-92. PubMed ID: 19427741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interim report of image-guided conformal high-dose-rate brachytherapy for patients with unfavorable prostate cancer: the William Beaumont phase II dose-escalating trial.
    Martinez AA; Kestin LL; Stromberg JS; Gonzalez JA; Wallace M; Gustafson GS; Edmundson GK; Spencer W; Vicini FA
    Int J Radiat Oncol Biol Phys; 2000 May; 47(2):343-52. PubMed ID: 10802358
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 43.